Non-invasive Ultra-early in Utero Detection and Precision CRISPR-mediated Correction of Monogenic Embryonic Mutations: A Critical Appraisal of a Hypothetical Therapeutic Framework
Aug 2026· Asian Journal of Medicine and Health· 0 citations
TL;DR
Whether that proposition that a pathogenic single-gene variant might be identified non-invasively at the earliest stage of pregnancy and corrected in situ before irreversible pathology develops is presently coherent as a therapeutic framework is examined.
Abstract
Advances in circulating placental DNA analysis and in programmable genome editing have developed largely in parallel, yet their conjunction has generated an increasingly discussed proposition: that a pathogenic single-gene variant might be identified non-invasively at the earliest stage of pregnancy and corrected in situ before irreversible pathology develops. This review examines whether that proposition is presently coherent as a therapeutic framework, rather than merely attractive as an idea. The analysis synthesises evidence on the provenance and kinetics of cell-free placental DNA, the analytical performance of relative mutation dosage, relative haplotype dosage, targeted haplotyping and cell-based prenatal diagnosis, and the preclinical record of nuclease-dependent editing, base editing and prime editing delivered to the fetal compartment by viral and lipid-nanoparticle carriers. Evidence quality was appraised with attention to study design, model relevance, endpoint validity, replication and the distance between mechanistic demonstration and clinical benefit. Three findings dominate. First, the detection half of the framework is constrained less by sequencing chemistry than by biology: circulating fetal-derived DNA is placental in origin, is present at low fractional abundance in the earliest weeks, and is an imperfect proxy for the fetal genotype. Second, the therapeutic half rests almost entirely on rodent studies in which editing efficiencies, delivery routes and endpoints do not correspond to the requirements of a human first-trimester intervention, and the only in utero therapies tested in human pregnancies have been protein and cell based rather than gene editing. Third, the interval implied by ultra-early diagnosis is precisely the interval in which delivery, dosing and germ-cell exposure are least characterised. The framework is therefore best regarded as a research programme with identifiable and testable intermediate objectives, not as an imminent clinical pathway. Priorities include gestational-age-resolved fetal fraction studies, editing outcome measurement at single-cell resolution, large-animal dosimetry, and governance work addressing the somatic and germline boundary in prenatal intervention.
This review focuses on analytical and translational frameworks for CRISPR fidelity assessment, with emphasis on the strengths and limitations of current bioanalytical platforms.
Arpita Mukherjee· Journal of Rare Diseases· 1 citation
Circulating fetoplacental nucleic acids have transformed prenatal medicine within a single generation, and screening based on cell-free DNA (cfDNA) is now offered routinely in many health systems. The field is moving quickly from the detection of whole-chromosome aneuploidy towards earlier sampling, sub-chromosomal resolution, monogenic diagnosis and the interrogation of epigenetic marks, yet the evidence supporting these extensions is uneven and the downstream consequences for children are rarely examined. This critical narrative review evaluates the state of knowledge on early prenatal detection of fetal genetic variants and epigenetic alterations through maternal blood sampling, and appraises the paediatric implications of an expanding prenatal detection frontier. Literature was identified through structured searching of Europe PMC and MEDLINE, Crossref Metadata Search, OpenAlex, Semantic Scholar and targeted retrieval of professional society statements, supplemented by backward and forward citation tracking. Evidence was appraised for design adequacy, confirmatory testing, spectrum of enrolled participants, and separation of analytical from clinical validity. Three findings dominate the synthesis. First, diagnostic confidence declines sharply and predictably as the target moves from common autosomal trisomies to rare autosomal trisomies, copy number variants and single-gene conditions, and this gradient is driven more by target prevalence and by placental biology than by sequencing chemistry. Second, DNA methylation currently functions far more securely as an analytical instrument, supporting fractional quantification and tissue-of-origin deconvolution, than as a validated diagnostic target for fetal disease, and the developmental literature that motivates epigenetic prediction rests overwhelmingly on postnatal tissues rather than on prenatal plasma. Third, paediatric evidence is the weakest link in the chain: prenatal detection demonstrably alters the ascertainment and the age distribution of childhood diagnoses, but longitudinal outcome data for prenatally ascertained children remain scarce. Priorities include phenotype-linked birth cohorts of prenatally screened pregnancies, prospective validation of methylation-based classifiers against paediatric endpoints, and evaluation frameworks that treat placental discordance as clinical information rather than analytical noise.
S. Bittmann, E. Luchter, E. Moschüring-Alieva· Asian Journal of Pediatric R...· 0 citations
CRISPR has progressed from an experimental genome-engineering technology to a clinically relevant therapeutic platform, although its future impact will depend on the ability to combine molecular precision and durable therapeutic benefit with rigorous safety assessment, responsible governance, and equitable access across diverse populations and healthcare systems.
G. Alejandro, Ortega Moreno, G. Amaya et al.· International science journa...· 0 citations
Human development begins with the fusion of sperm and oocyte, yet the maternal genome plays a far more active and essential role than traditionally appreciated. This review critically examines the influence of maternal genetic integrity on embryogenesis and offspring health, emphasizing that the maternal genome is not merely a passive donor of half the DNA, but a vital architect of early life. We explore the role of maternal effect genes (MEGs) in orchestrating early zygotic development, detailing their functions in epigenetic regulation, mitochondrial dynamics, DNA repair, and cell division. A curated reference of MEGs, spanning mouse models and human pathogenic variants, is presented to support future research and clinical diagnostics. Beyond early embryonic development, maternal genetic integrity has lasting implications for offspring well-being. Errors in DNA replication and repair machinery within the maternal germline can lead to de novo variants (DNVs)-spontaneous germline variants that can be passed on to the offspring and impact their health at different ages. We highlight an underappreciated contribution of maternally derived DNVs to a growing list of sporadic disorders and present the first comprehensive catalogue of associated diseases. We further examine DNVs compatible with multigenerational transmission, investigating how maternal age and mutational processes-such as recombination errors and epigenetic drift-influence both disease risk and evolutionary outcomes. By integrating insights from developmental biology, genomics, and reproductive medicine, this review reframes the maternal genome as a dynamic and fragile foundation upon which life depends-offering new directions for understanding fertility, sporadic disease, and intergenerational health.
Xuebi Cai, K. Hutt, Amy L. Winship et al.· Endocrine reviews· 0 citations
Rare diseases, most of which have a genetic basis, remain a major challenge due to diagnostic delays and limited therapeutic options, particularly within the Middle Eastern regions. These countries exhibit a heightened prevalence of genetic disorders attributable to their distinctive genetic architecture. Advances in long-read sequencing (LRS) technologies have significantly improved our ability to detect complex genetic variations, including structural variants (SVs), repeat expansions, and mutations in previously inaccessible genomic regions, thereby increasing the diagnostic yield in rare disease cohorts. In parallel, the rapid evolution of gene-editing platforms such as CRISPR/Cas9, base editors, and prime editors has opened new possibilities for addressing the biological pathways of the disease and achieving precise therapeutic correction of pathogenic variants causing the disease. Importantly, the integration of LRS with gene-editing approaches establishes a continuum from accurate variant discovery and functional characterization to the development of personalized therapies. This review highlights recent progress in both fields, discusses their complementary roles in rare disease research, and explores the translational opportunities and ethical challenges of combining these technologies to advance precision medicine. In addition, the review addresses emerging ethical and regulatory considerations associated with the clinical translation of long-read sequencing and next-generation gene-editing technologies, particularly in the context of rare disease precision medicine.
Anshida Konamveettil Abdul Latheef, Mohammad Ali, O. Farahat et al.· Frontiers in Medicine· 0 citations
This article synthesizes contemporary advancements in CRISPR-mediated mammalian genome modification, detailing core mechanisms – such as guide RNA and the Cas9 endonuclease – alongside next-generation modalities, including base and prime editing.
Olga Aldoshina, Dmitriy Lazarev, E. Smirnova· Veterinariya, Zootekhniya i...· 0 citations
